Cinaciguat
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | intravenous (?) |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C36H39NO5 |
Molar mass | 565.710 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.
Mechanism of action
Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1]
See also
- Riociguat, another drug stimulating sGC, but with a different mechanism
- PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.
References
- ^ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles with changed ChemSpider identifier
- Articles with changed InChI identifier
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Vasodilators
- Benzoic acids
- Phenol ethers
- All stub articles
- Cardiovascular system drug stubs